Stack
A GLP-1 with 5-Amino-1MQ
An incretin agonist doing the established work, with an oral NNMT inhibitor added on a mechanism that has never been tested in a person. One half of this has phase 3 trials; the other half has mice.
The GLP-1 is the part that works. Semaglutide, tirzepatide and retatrutide have large human trials behind them, and in a weight-loss stack they are doing essentially all of the measurable work. Anything added alongside is being asked to improve on a drug that already produces the largest effect in the category.
5-Amino-1MQ is the addition, and the argument for it is a chain of inferences: it inhibits NNMT, NNMT consumes the methyl donor that feeds NAD+ synthesis, higher NAD+ is associated with more active fat metabolism, therefore inhibiting NNMT should assist fat loss. Each link has support in cell and rodent work. The chain as a whole has never been tested in a human being, and the compound has no completed human trial of any kind.
That asymmetry is the whole story of this stack and it is why we have written it up rather than left it alone. Someone running both and losing weight has learned nothing about the 5-Amino-1MQ. The GLP-1 explains the result on its own. Attribution is the problem here, not safety, and no amount of personal logging solves it.
It is also worth naming what makes this pairing attractive independent of evidence: the oral compound is cheap, needs no needle, and its proposed mechanism targets visceral fat specifically, which is the fat people most want to lose and the one a scale cannot distinguish.
The schedule
Commonly run, not recommended16 weeks. Doses are what sources describe rather than what we advise — where a source gave a range we show the range instead of choosing a number inside it.
| Compound | Dose | How often | Weeks |
|---|---|---|---|
| RetatrutideEarly human trialsThe established half. A triple incretin agonist producing the largest reported weight reduction in the class. | 1 mg–12 mg | Weekly · MonTitrated upward over months in the trials rather than started at a target dose, and the gastrointestinal side effects are dose-dependent. Semaglutide or tirzepatide substitute here on the same weekly schedule at their own dose scales. | 1–16 |
| 5-Amino-1MQPreclinicalThe speculative half. An oral NNMT inhibitor, added on a proposed NAD+ mechanism with no human evidence. | 50 mg–150 mg | Once dailyDoses in circulation are extrapolated from rodent studies by body weight. This is not how human dosing is established. There is no human pharmacokinetic data to say what an oral dose actually achieves in blood. | 1–16 |
Things worth knowing
- Nothing in either compound's record describes an interaction between them. That is not reassurance. It reflects the fact that nobody has studied the combination, which is a different statement from having studied it and found it safe.
- The GLP-1 will account for the weight change. If the point of adding the second compound is to find out whether it does anything, running them together makes that impossible to answer.
- Appetite suppression from an incretin agonist reduces food intake, and reduced intake changes the nutrient supply the NAD+ pathway is being asked to work with. The two are not independent even in theory.
- 5-Amino-1MQ is sold as a research chemical with no pharmacopoeial standard, so oral capsule content is unverified. A certificate of analysis for the batch is the only check available and it is not a strong one.
- Anyone on a GLP-1 for a diagnosed condition should be talking to whoever prescribed it before adding anything, and that is a stronger recommendation here than on most of these pages.
Related
Questions
- Does 5-Amino-1MQ add anything to a GLP-1?
- Nobody knows, and running both together is the arrangement least likely to find out. There is no human trial of 5-Amino-1MQ at all, and in this pairing the incretin agonist accounts for the weight change on its own. Anyone reporting good results from the combination has results explained entirely by the half that already had phase 3 trials.
- Which GLP-1 do people pair it with?
- All of them. Semaglutide, tirzepatide and retatrutide are used interchangeably here, on their own dose scales and the same weekly schedule. The choice between them is a decision about the GLP-1 and has nothing to do with the second compound; our comparisons cover how they actually differ.
- Is 5-Amino-1MQ a peptide?
- No. It is a small molecule taken orally, and it is sold alongside peptides rather than being one. That matters practically: there is no vial to reconstitute, no injection, and no syringe arithmetic. There is also no pharmacopoeial standard for what is in an oral capsule.
- Do the two interact?
- Nothing in either compound's record describes an interaction. That is a statement about what has been studied, not a finding of safety. The combination has never been tested, which is different from having been tested and found clear.
- How long do people run this?
- The GLP-1 side is open-ended in practice, because stopping an incretin agonist is generally followed by weight regain. 5-Amino-1MQ is usually described in blocks of eight to sixteen weeks. Neither figure comes from a trial of the combination.
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.